JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
US$218,42
arrow_downward
-1,81%(-4,03) 1D
US$218,42
0,00% (0,00)
bedtimeAfter hours
Closed: 9 ຕ.ລ., 16 ໂມງ 0 ນາທີ 01 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for JAZZ...
Open
US$221,79
High
US$227,00
Low
US$213,20
Mkt. cap
14,18 ຕື້
Avg. vol.
935,53 ພັນ
Volume
1,29 ລ້ານ
P/E ratio
14,93
52-wk high
US$266,38
52-wk low
US$128,80
EPS
US$14,63
Beta
0,37
Shares outstanding
64,92 ລ້ານ
No. of employees
3 ພັນ
Open
US$221,79
High
US$227,00
Low
US$213,20
Mkt. cap
14,18 ຕື້
Avg. vol.
935,53 ພັນ
Volume
1,29 ລ້ານ
P/E ratio
14,93
52-wk high
US$266,38
52-wk low
US$128,80
EPS
US$14,63
Beta
0,37
Shares outstanding
64,92 ລ້ານ
No. of employees
3 ພັນ
News stories
From web sources and news partners
Investing.com Nigeria
·
12 ຊົ່ວໂມງກ່ອນ
Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 11 October
TipRanks
·
2 ມື້ກ່ອນ
Jazz Pharmaceuticals Plans Commercial Leadership Transition Ahead
ChartMill
·
2 ມື້ກ່ອນ
Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stock
AD HOC NEWS
·
3 ມື້ກ່ອນ
Truist raises target for Jazz Pharmaceuticals stock to USD 286.00
Profile
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC
CEOBruce C Cozadd
Employees2,89 ພັນ
Founded2003
Headquarters-
SectorPharmaceutical industry
Websitejazzpharma.com